GammaCan to Present at the MarketReach America Conference in Maryland
June 19 2006 - 6:30AM
Business Wire
GammaCan International (OTC BB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that
Patrick Schnegelsberg, Chief Executive Officer, will be presenting
at the MarketReach America Conference on June 21st at the Mt.
Washington Conference Center in Baltimore, Maryland. Patrick
Schnegelsberg will provide an update on the Company's pipeline to
treat cancer and discuss VitiGam, GammaCan's lead program to treat
malignant melanoma. About VitiGam: VitiGam is a second generation
intravenous IgG-based product and a first-in-class anti-cancer
immunotherapy. GammaCan plans on having VitiGam to enter phase I/II
testing under a US IND in the near future and the Company recently
held a pre-IND meeting with the FDA. VitiGam is being designed to
target metastatic melanoma patients with Stage III and IV melanoma.
VitiGam is an IgG product that is different from standard IgGs: It
is manufactured from the plasma of donors with vitiligo, a benign
autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IgG (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IgG in general. About
GammaCan: GammaCan is focusing on the commercialization of an
innovative anti-cancer immunotherapy to treat metastatic cancer.
GammaCan's platform is based on IgG, a safe, relatively non-toxic
human plasma-based product, currently used to treat a variety of
immune deficiencies and autoimmune diseases. IgG works by
strengthening the patient's immune system. Many experts currently
view immunotherapy as a future alternative to today's standard
chemotherapy. GammaCan is developing VitiGam, its second generation
program. VitiGam is an IgG derived from the plasma of vitiligo
donors and is being developed to treat malignant melanoma. GammaCan
owns, and has applied for US patent protection covering the use of
IgG and vitiligo-derived IgG (VitiGam). For more information about
GammaCan visit www.GammaCan.com or call the company's headquarters
in Giv'at Shmuel, Israel at 972 3 5774475 or toll free
1-866-308-0396 (from North America). About MarketReach America:
MarketReach America is an award winning program that brings leading
edge Israeli tech companies to Maryland for investment and
strategic partnering opportunities. MarketReach America is a
program of the Maryland/Israel Development Center (MIDC), an
alliance of the Maryland Department of Business and Economic
Development, Israel's Ministry of Industry and Trade and The
ASSOCIATED: Jewish Community Federation of Baltimore. The program
is conducted in partnership with The Trendlines Group, the MIDC
representative in Israel. The MIDC is the only organization that
has been awarded three successive grants from the bi-national
US-Israel Science and Technology Foundation to run such a
partnering program. Safe Harbor Statement: Statements in this
document that are not purely historical are forward-looking
statements. Forward-looking statements in this release include
statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment.
Actual outcomes and the Company's actual results could differ
materially from those in such forward-looking statements. Factors
that could cause actual results to differ materially include risks
and uncertainties such as the inability to finance the planned
development of the technology, inability to hire appropriate staff
to develop the technology, unforeseen technical difficulties in
developing the technology, inability to obtain regulatory approval
for human use, competitors' therapies proving more effective,
cheaper or otherwise preferable for consumers, inability to market
the product we produce, among other factors, all of which could
among other things, delay or prevent product release or cause our
company to fail. For further risk factors see the risk factors
associated with other early stage medical research and development
companies filed with the SEC on EDGAR.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024